Status:
COMPLETED
The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation
Lead Sponsor:
Johns Hopkins University
Conditions:
Patients Active and Listed for Lung Transplantation
Eligibility:
All Genders
18-66 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to compare outcomes in patients undergoing lung transplantation, using 2 different induction therapies. Primary outcome is survival and secondary outcomes include freedom ...
Detailed Description
Acute and chronic allograft rejection are two of the common problems limiting and complicating the utility of lung transplantation. The timing and frequency of acute rejection has been shown to be a s...
Eligibility Criteria
Inclusion
- All patients accepted and listed for lung transplantation will be considered for randomization
Exclusion
- Patients who demonstrate hemodynamic instability, requiring inotropes for greater than 48 hours prior to transplant
- Severe reperfusion pulmonary edema or primary graft dysfunction requiring FiO2 of \> 50% and PEEP \> 10 cm for greater than 48 hours prior to transplant
- Preoperative renal insufficiency (CrCl \< 50 gm.d or serum creatinine \> 2.0)
- Pre-operative panel reactive antibodies PRA
- Preoperative recipient bacterial or fungal colonization
- Preoperative antimicrobial suppressive therapy
Key Trial Info
Start Date :
October 1 1999
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00181142
Start Date
October 1 1999
End Date
December 1 2004
Last Update
December 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University Hospital
Baltimore, Maryland, United States, 21287